Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2804470 | 0.98 | ALDH1A1 (0.48) | ALDH1A1TSHRSIGMAR1HRH3GAA | |
| Hydrochloric Acid SCHEMBL6339465 | 0.96 | ALDH1A1 (0.47) | ALDH1A1TSHRSIGMAR1HRH3GAA | |
| SCHEMBL10310285 | 0.92 | SIGMAR1 (0.50) | ALDH1A1TSHRSIGMAR1HRH3SMN1; SMN2 | |
| SCHEMBL8000929 | 0.88 | CA12 (0.53) | ALDH1A1TSHRHRH3L3MBTL1 | |
| Guanethidine SCHEMBL28254486 | 0.88 | CA12 (0.53) | ALDH1A1TSHRHRH3L3MBTL1 | |
| Guanethidine SCHEMBL34753 | 0.88 | CA12 (0.53) | ALDH1A1TSHRHRH3L3MBTL1 | |
| Guanethidine SCHEMBL3128359 | 0.86 | CA12 (0.52) | ALDH1A1TSHRL3MBTL1 | |
| Guanethidine SCHEMBL22127050 | 0.86 | CA12 (0.52) | ALDH1A1TSHRL3MBTL1 | |
| Hydrochloric Acid SCHEMBL28128869 | 0.86 | CA12 (0.52) | ALDH1A1TSHRL3MBTL1 | |
| Guanethidine SCHEMBL15514378 | 0.86 | CA12 (0.52) | ALDH1A1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068710-A1 | COMPOUNDS COMPRISING AN IMIDAZOLE CORE | Tay Therapeutics Limited (GB) | 2025-04-03 | — | — | WO | disclosed |
| EP-2379506-B1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8357694-B2 | Substituted 5,6-dihydro-6-phenylbenzo[F]isoquinolin-2-amine compounds | ARQULE, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239525-A1 | SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F]ISOQUINOLIN-2-AMINE COMPOUNDS | NQO1, DPYD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 510/4885TSHR 4709/4885SIGMAR1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.